EVOLVING DECISIONS AND BEST PRACTICES
MANAGEMENT OF EGFR-MUTATED NSCLC

TUESDAY, OCTOBER 17, 2017 | 12:45 – 14:15

VENUE: PACIFICO YOKOHAMA CONVENTION CENTER
1-1-1 MINATOMIRAI, NISHI-KU, YOKOHAMA 220-0012, JAPAN
ROOM: MAIN HALL | LUNCH WILL BE SERVED

To register, please visit:
www.medscape.org/townhall/egfr-registration

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP

FACULTY

Suresh S. Ramalingam, MD
Professor of Hematology and Medical Oncology
Roberto C. Goizueta Chair for Cancer Research
Assistant Dean for Cancer Research
Deputy Director
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia, United States

Lecia V. Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts, United States

Rolf A. Stahel, MD
Chair
Cancer Center Zurich
Head
Thoracic Oncology Center
University Hospital Zurich
Zurich, Switzerland

Heather A. Wakelee, MD
Associate Professor of Medicine, Oncology
Stanford University
Faculty Director
Cancer Clinical Trials Office
Stanford Cancer Institute
Stanford, California, United States
AGENDA
12:30 – 12:45
Registration and Lunch

12:45 – 12:50
Welcome and Introductions

12:50 – 13:05
The Evolving Treatment Algorithm in EGFR-Mutated NSCLC

13:05 – 13:25
Diagnosis and Management on the Frontline

13:25 – 13:45
Case Examples of Second-Line Management

13:45 – 14:00
Sequencing Therapy to Improve Outcomes

14:00 – 14:05
Concluding Remarks

14:05 – 14:15
Question and Answer Session

Target Audience
This activity is intended for oncologists, pulmonologists, pathologists, and radiologists.

Goal Statement
This activity aims to assist healthcare providers with incorporating appropriate selection of first-line and subsequent lines of EGFR tyrosine kinase inhibitor therapy into their practice in order to improve overall management of EGFR-mutated NSCLC.

Learning Objectives
Upon completion of this activity, participants will:
- Have increased knowledge regarding
  - Clinical trial data in the management of EGFR-mutated NSCLC across the care continuum
- Have greater competence related to
  - Ordering biomarker testing for patients with advanced NSCLC throughout the continuum of their disease
  - Selecting the most appropriate regimen for patients with EGFR-mutated advanced NSCLC
  - Mitigating treatment-related adverse events in patients with EGFR-mutated advanced NSCLC

Accreditation Statement
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To register, please visit:
www.medscape.org/townhall/egfr-registration